Authors: | Sissung, T. M.; Peer, C. J.; Korde, N.; Mailankody, S.; Kazandjian, D.; Venzon, D. J.; Landgren, O.; Figg, W. D. |
Article Title: | Carfilzomib and lenalidomide response related to VEGF and VEGFR2 germline polymorphisms |
Abstract: | The combination of carfilzomib, lenalidomide, and dexamethasone (CRd) has induced deep responses in patients with newly diagnosed multiple myeloma. While vascular endothelial growth factor (VEGF) pathway polymorphisms have been associated with clinical outcomes for antiangiogenesis agents, we explored associations between such polymorphisms and CRd clinical response. The VEGF-1498C>T (rs833061) and VEGFR2 V297I (rs2305948) were associated with CRd response (OR ≤ 0.10, P ≤ 0.009), whereas VEGF-1498C>T and VEGFR2 Q472H (rs1870377) were associated with minimum residual disease negativity (P ≤ 0.023). As these SNPs were not associated with disease parameters (e.g., plasma VEGF, albumin, or beta-2-microglobin concentration), data suggest these SNPs may be markers of CRd response. © 2017, Springer-Verlag Berlin Heidelberg (outside the USA). |
Keywords: | vasculotropin; cancer survival; clinical article; controlled study; protein expression; treatment outcome; vascular endothelial growth factor a; single nucleotide polymorphism; genetics; polymorphism, single nucleotide; lenalidomide; thalidomide; angiogenesis inhibitor; cancer combination chemotherapy; unspecified side effect; cancer patient; comparative study; antineoplastic agent; protein blood level; progression free survival; multiple cycle treatment; multiple myeloma; antineoplastic combined chemotherapy protocols; genetic association; genotype; gene frequency; dexamethasone; pathology; vasculotropin receptor 2; vascular endothelial growth factor receptor-2; heterozygote; albumin; dna; minimal residual disease; drug response; vascular endothelial growth factor; vasculotropin a; drug clearance; beta 2 microglobulin; pharmacogenetics; angiogenesis inhibitors; oligopeptides; dna extraction; carfilzomib; polymorphism; oligopeptide; drug disposition; albumin blood level; vascular endothelial growth factor receptor; kdr; humans; human; priority journal; article; analogs and derivatives; isoetarine |
Journal Title: | Cancer Chemotherapy and Pharmacology |
Volume: | 80 |
Issue: | 1 |
ISSN: | 0344-5704 |
Publisher: | Springer |
Date Published: | 2017-07-01 |
Start Page: | 217 |
End Page: | 221 |
Language: | English |
DOI: | 10.1007/s00280-017-3323-8 |
PUBMED: | 28488026 |
PROVIDER: | scopus |
PMCID: | PMC6387687 |
DOI/URL: | |
Notes: | Article -- Export Date: 1 August 2017 -- Source: Scopus |